Clinical Trials Browser

Lymphoma, Non-Hodgkin, Multiple Myeloma, Neoplasms

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

Breast Neoplasms

Prostatic Neoplasms

Adenocarcinoma, Prostatic Neoplasms

Prostatic Neoplasms

Breast Neoplasms

Neoplasm Metastasis, Neoplasms, Recurrence

Small Cell Lung Carcinoma

Carcinoma, Transitional Cell

Breast Neoplasms

Carcinoma, Squamous Cell

Endometrial Neoplasms

Fallopian Tube Neoplasms, Ovarian Neoplasms

Glioblastoma, Glioma

Breast Neoplasms, Triple Negative Breast Neoplasms

Prostatic Neoplasms

Advanced Breast Cancer

Breast Neoplasms

Neoplasm Metastasis

Premenopausal HR+/HER2- Metastatic Breast Cancer

Carcinoma, Renal Cell

Breast Neoplasms, Triple Negative Breast Neoplasms

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Gastrointestinal Neoplasms

Triple Negative Breast Neoplasms

Colorectal Neoplasms

Breast Adenocarcinoma

Triple Negative Breast Neoplasms

Endometrial Neoplasms

Prostate Cancer Metastatic

Breast Neoplasms, Triple Negative Breast Neoplasms

Mesothelioma, Malignant

Clinical Trials

TAPUR

I-SPY

Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial

Presurgical Phase II Study of Talazoparib in Combination With Enzalutamide in Prostate Cancer

TALENT

Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer

Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer

Talazoparib in Treating Patients With Recurrent, Refractory, Advanced, or Metastatic Cancers and Alterations in the BRCA Genes

TRIO-US L-07

TALASUR

Talazoparib Monotherapy in PALB2 Mutation Associated Advanced Breast Cancer

Phase II Study of Atezolizumab and Tiragolumab With ctDNA for HPV-positive SCC

Avelumab in Patients With MSS, MSI-H and POLE-mutated Recurrent or Persistent Endometrial Cancer and of Avelumab/Talazoparib and Avelumab/Axitinib in Patients With MSS Recurrent or Persistent Endometrial Cancer

ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer

TAC-GReD

PERSEVERE

ZZ-First

Talazoparib in Advanced Breast Cancer Patients With Homologous Recombinant Deficiency

FUTURE

Nivolumab in Combination With Talazoparib in Melanoma and Mutations in BRCA or BRCA-ness Genes

Young-PALETTA

Talazoparib and Avelumab in Participants With Metastatic Renal Cell Carcinoma

DRUP

TARA

ROME

Phase II Trial of Talazoparib in BRCA1/2 Wild-type HER2-negative Breast Cancer and Other Solid Tumors

EVIDENT

Talazoparib Before Standard Therapy in Treating Patients With Invasive, BRCA-Mutated Breast Cancer

Efficacy of Talazoparib in Asian Metastatic Breast Cancer Patients With a Homologous Recombinant Deficiency (HRD) Signature

PANDA

Telaglenastat + Talazoparib In Prostate Cancer

Talazoparib Maintenance Therapy in Triple-negative Breast Cancer

TALAMESO